• participation of Iceland and Norway in EMEA activities • continued active participation in and support to ICH with finalisation of the ‘common technical document’ in 2000 and implementation in 2001 • development of new activities in favour of orphan medicinal products • continued collaboration with central and eastern European countries in the framework of the simplified procedure for the recognition of centrally authorised products (CADREAC agreement) and the PERF initiative • collaboration with the European Monitoring Centre for Drugs and Drug Addiction in the field of risk assessment for new synthetic drugs will continue to increase